Zoetis Inc (NYSE:ZTS) Holdings Lifted by Candriam Luxembourg S.C.A.

Candriam Luxembourg S.C.A. boosted its position in shares of Zoetis Inc (NYSE:ZTS) by 1.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 42,382 shares of the company’s stock after buying an additional 672 shares during the quarter. Candriam Luxembourg S.C.A.’s holdings in Zoetis were worth $5,609,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Institute for Wealth Management LLC. acquired a new position in shares of Zoetis in the 4th quarter valued at $25,000. Tarbox Family Office Inc. boosted its position in shares of Zoetis by 74.4% in the 3rd quarter. Tarbox Family Office Inc. now owns 218 shares of the company’s stock valued at $27,000 after purchasing an additional 93 shares during the period. Savior LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $30,000. Corbenic Partners LLC acquired a new position in shares of Zoetis in the 4th quarter valued at $31,000. Finally, Atlas Capital Advisors LLC acquired a new position in shares of Zoetis in the 3rd quarter valued at $33,000. 90.04% of the stock is owned by institutional investors and hedge funds.

ZTS has been the subject of a number of recent analyst reports. Raymond James initiated coverage on Zoetis in a research report on Thursday, January 9th. They issued a “market perform” rating for the company. Cfra upgraded Zoetis from a “buy” rating to a “strong-buy” rating and increased their price target for the company from $147.00 to $160.00 in a research report on Thursday. Bank of America reiterated a “hold” rating and issued a $145.00 price target on shares of Zoetis in a research report on Wednesday. SunTrust Banks reiterated a “hold” rating and issued a $145.00 price target on shares of Zoetis in a research report on Friday. Finally, Morgan Stanley increased their price target on Zoetis from $136.00 to $148.00 and gave the company an “equal weight” rating in a research report on Friday. Eight equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and an average price target of $135.53.

Shares of Zoetis stock opened at $144.17 on Friday. The stock has a 50-day moving average price of $136.94 and a 200 day moving average price of $127.01. The company has a market cap of $68.67 billion, a P/E ratio of 47.58, a P/E/G ratio of 3.10 and a beta of 0.81. The company has a current ratio of 4.39, a quick ratio of 3.02 and a debt-to-equity ratio of 2.47. Zoetis Inc has a 1 year low of $91.21 and a 1 year high of $146.26.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, February 13th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.04. The firm had revenue of $1.67 billion during the quarter, compared to the consensus estimate of $1.64 billion. Zoetis had a return on equity of 70.78% and a net margin of 23.76%. The business’s revenue for the quarter was up 7.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.79 EPS. On average, equities analysts forecast that Zoetis Inc will post 3.6 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, April 17th will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 0.55%. The ex-dividend date is Thursday, April 16th. Zoetis’s dividend payout ratio is currently 25.56%.

In related news, EVP Heidi C. Chen sold 1,179 shares of the stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $134.58, for a total value of $158,669.82. Following the completion of the sale, the executive vice president now directly owns 12,642 shares of the company’s stock, valued at approximately $1,701,360.36. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Roxanne Lagano sold 4,463 shares of the stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $118.99, for a total value of $531,052.37. Following the completion of the sale, the executive vice president now directly owns 33,190 shares of the company’s stock, valued at $3,949,278.10. The disclosure for this sale can be found here. Over the last three months, insiders sold 125,001 shares of company stock valued at $15,342,770. Company insiders own 0.29% of the company’s stock.

Zoetis Profile

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

Read More: What is a stock buyback?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.